Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...

The first is an Opdivo and Yervoy combination for advanced melanoma, the first such immuno-oncology combination therapy approved. The second is for Emplicti, developed with AbbVie for multiple ...

The US FDA has approved the combined use of Bristol-Myers Squibb's melanoma drugs Yervoy and Opdivo, a highly effective but pricey treatment regimen. This is the first time that two immuno ...

Recommendation is based primarily on results from the Phase 3 CheckMate -67T trial which demonstrated noninferiority in the co-primary endpoints of C avgd28 and C minss and consistent efficacy in the ...

It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of ...

has recommended approval of a new Opdivo ® (nivolumab) formulation associated with a new route of administration (subcutaneous use), a new pharmaceutical form (solution for injection) and a new ...

its intravenous formulation A decision on the EU Opdivo extension of marketing authorization ... monotherapy maintenance following completion of nivolumab plus Yervoy (ipilimumab)combination ...

Bristol Myers Squibb said a key European regulatory committee is backing a formulation of its blockbuster cancer drug Opdivo that can be injected under the skin.

The phase 2 GIANT trial will evaluate Opdivo with or without relatlimab in IDH-wildtype newly diagnosed glioblastoma.

Bristol Myers (BMY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval ...